No Data
No Data
Is Yunnan Baiyao GroupLtd (SZSE:000538) Using Too Much Debt?
Yunnan Baiyao Group (000538.SZ): Its anti-hair loss and care product, Yangyuanqing, has a patented anti-hair loss formula that can effectively reduce scalp oil secretion and inhibit hair loss caused by excessive oil secretion.
Yunnan Baiyao (000538.SZ) stated on the investor interaction platform on September 19th that its anti-hair loss and hair care product, Yang Yuan Qing, has a patented anti-hair loss formula that can effectively reduce scalp oil secretion and inhibit excessive oil secretion that leads to hair loss. This product has also been developed with advanced DHT blocking technology, which prevents seborrheic hair loss by inhibiting the expression of DHT-induced TGFβ (recent studies have shown that DHT is the main cause of seborrheic hair loss. When DHT binds to hair follicle cells, it causes hair follicle contraction, thereby stopping hair growth).
Yunnan Baiyao Group (000538.SZ): has a variety of medications for cardiovascular and cerebrovascular diseases.
Yunnan Baiyao (000538.SZ) stated on the investor interaction platform on September 19th that the company has multiple drugs for cardiovascular and cerebrovascular diseases. Compound Danshen Tablet, indications: promoting blood circulation and removing blood stasis, regulating qi and relieving pain. Used for chest pain caused by qi stagnation and blood stasis, symptoms include chest tightness and precordial pain; stable angina pectoris and cerebral infarction with the above symptoms. Ginkgo Biloba Leaf, indications: promoting blood circulation and removing blood stasis, dredging collaterals. Used for chest pain, heart pain, stroke, hemiplegia, slurred speech caused by blood stasis obstruction of collaterals; stable angina pectoris and cerebral infarction with the above symptoms. Ningxinbao Capsule, indications: improving sinus rhythm, improving sinoatrial node and atrioventricular conduction.
Yunnan Baiyao Group (000538.SZ): The company achieved overseas revenue of 0.634 billion yuan in the entire year of 2023, a year-on-year growth of 51.25%.
Yunnan Baiyao (000538.SZ) stated on the investor interaction platform on September 19th that the company achieved overseas revenue of 0.634 billion yuan in 2023, a year-on-year increase of 51.25%. Yunnan Baiyao continues to enhance and improve its international capacity building, steadily promoting the internationalization process of the company. As a national treasure of traditional chinese medicine and inheritor of traditional chinese medicine culture, Yunnan Baiyao actively develops and expands international business, establishes local service entities in stages, promotes the publicity of traditional chinese medicine culture and locally registers and sells products, contributing its own efforts to the promotion of traditional chinese medicine culture and products overseas.
Estimating The Intrinsic Value Of Yunnan Baiyao Group Co.,Ltd (SZSE:000538)
Founder Securities: Traditional Chinese medicine sector H1 performance is under short-term pressure. The performance of branded OTC companies is better than the industry as a whole.
Due to the impact of high base in the same period of 23Q2 and external factors such as centralized procurement and same-price policy, the performance of the traditional Chinese medicine sector in Q2 is under pressure compared to the same period last year, and it also declined compared to Q1.